S23

    • S23

    S23 is an oral selective androgen receptor modulator (SARM). The drug was originally developed by GTX Inc. as a male hormonal contraceptive. It has a high affinity for the androgen receptor with a Ki value of 1.7 nM. A study published by Jones et al. compared the effectiveness of S23 in castrated and uncastrated male rats.

    $80


    Contact us
    Category:

    S23


    S23 is an oral selective androgen receptor modulator (SARM). The drug was originally developed by GTX Inc. as a male hormonal contraceptive. It has a high affinity for the androgen receptor with a Ki value of 1.7 nM. A study published by Jones et al. compared the effectiveness of S23 in castrated and uncastrated male rats.


    Effects of S23 on Fertility


    In castrated male rats, S23 was effective at doses of 0.43 mg/day in the prostate and 0.079 mg/day in the levator ani muscles. In intact male rats, doses above 0.1 mg/day resulted in greater than 50% suppression of luteinizing hormone (LH). This dose was associated with a decrease in prostate size and an increase in levator ani muscle size.

    In a study of intact male subjects treated with S23 and estradiol benzoate (to maintain sexual activity), sperm was not found in the testes of 4 of 6 subjects after 10 weeks. Furthermore, none of the six experimental animals reported pregnancy. After treatment, infertility was completely reversible; all subsequent mating trials resulted inpregnancy.


    Effects of S23 on Muscle Mass and Body Fat


    The effects of S23 on muscle mass and body fat are similar to those of anabolic steroids. Studies in male rats have shown that treatment with S23 resulted in a decrease in total body weight and fat mass. The rats in this study were also administered estradiol benzoate to maintain sexual behavior. Although estrogen is known to cause muscle loss, the combination with S23 neutralized this effect and resulted in an increase in muscle mass in male rats.
    In addition, another study showed that S23 may be effective against muscle loss caused by long-term use of glucocorticoids. This study also investigated the effects of S23 on castration-induced muscle atrophy. Muscle loss was observed in both cases, but administration of S23 and testosterone blocked dexamethasone-induced Akt dephosphorylation. The results suggest that S23 may be an effective treatment for glucocorticoid-induced muscle loss. Concentration
    20 pg/vl.